Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shiota, G.
Right arrow Articles by Kawasaki, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shiota, G.
Right arrow Articles by Kawasaki, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1999 Oxford University Press

Article

Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice

Goshi Shiota2, Ken-ichi Harada, Masato Ishida, Yasushi Tomie, Michiko Okubo, Shunsuke Katayama, Hisao Ito1 and Hironaka Kawasaki

Second Department of Internal Medicine, Tottori University School of Medicine, Yonago 683-8504 and
1 First Department of Pathology, Tottori University School of Medicine, Yonago 683-8504, Japan

Glycyrrhizin (GL) is widely used in Japan as a therapeutic agent for chronic active liver diseases. However, its action on hepatocarcinogenesis remains to be elucidated. To clarify its effect, mice treated with diethylnitrosamine (NDEA) with or without GL were analyzed. Five-week-old male BALB/c mice were divided into two groups, GL (n = 50) and C (n = 47). Mice in the GL group intramuscularly received 2 mg of GL 3 days a week, and mice in the C group received the same volume of saline in the same way. After 2 weeks, the mice were treated with an i.p. injection of 75 mg/kg body wt of NDEA weekly for 3 weeks and 100 mg/kg body wt of NDEA weekly for the following 3 weeks. Thirty additional mice that did not receive NDEA treatment were divided into two groups, GC (n = 15) and SC (n = 15). They received GL or saline, respectively. Mice in the 4 groups were killed every 5 weeks after the last injection of NDEA from 7 weeks to 32 weeks. Liver function tests such as AST and albumin were significantly improved in the GL group compared with the C group (P < 0.05, each). Although liver nodules appeared in the C group at 22 weeks, they were not observed until 32 weeks in the GL group. At 32 weeks, the mean number of liver tumors, composed of adenoma and hepatocellular carcinoma (HCC), in the GL group was 0.71, which was significantly decreased compared with 1.64 of the C group (P < 0.05). The mean number of HCC in the GL group was 0.29/liver, which was lower than 0.82/liver in the C group (P < 0.05). The incidence rate of HCC at 32 weeks was 64% in the C group and 21% in the GL group (P < 0.05, C versus GL group). Our results suggest that GL treatment inhibits the occurrence of HCC.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Evid Based Complement Alternat MedHome page
J. R. Lee, S. J. Park, Y. K. Kwon, S. Y. Jee, J. Seo, H.-S. Lee, T. K. Kwon, and S. C. Kim
Hepatoprotective Activity of Licorice Water Extract against Cadmium-induced Toxicity in Rats
Evid. Based Complement. Altern. Med., August 9, 2007; (2007) nem078v1.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
H. Tsuda, A. Naito, C. K. Kim, K. Fukamachi, H. Nomoto, and M. A. Moore
Carcinogenesis and Its Modification by Environmental Endocrine Disruptors: In Vivo Experimental and Epidemiological Findings
Jpn. J. Clin. Oncol., June 1, 2003; 33(6): 259 - 270.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Oyama, G. Shiota, H. Ito, Y. Murawaki, and H. Kawasaki
Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats
Carcinogenesis, May 1, 2002; 23(5): 885 - 892.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Maruyama, N. Nagasue, D. K. Dhar, A. Yamanoi, O. N. El-Assal, K. Satoh, and K. Okita
Preventive Effect of FK143, a 5{{alpha}}-Reductase Inhibitor, on Chemical Hepatocarcinogenesis in Rats
Clin. Cancer Res., July 1, 2001; 7(7): 2096 - 2104.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.